GlassScriptPhysician profile
Angela Cherie Saunders
NPI 1932456308
$10,483.75
in general payments reported to CMS, 2019-2025
43 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $628 · 2021: $1,612 · 2022: $2,150 · 2023: $1,875 · 2024: $2,159 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,786 · Education: $90.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,786.23 |
| Education | $90.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,709.74 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $850.91 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $601.48 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $566.83 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $480.21 | 2022-2025 | Dupixent |
| Genzyme Corporation | $365.27 | 2022-2024 | |
| Gilead Sciences, INC. | $301.57 | 2022-2024 | Epclusa |
| Madrigal Pharmaceuticals | $276.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $242.19 | 2021-2025 | |
| Ardelyx, INC. | $238.24 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $219.08 | 2019-2025 | Sucraid, Sucraid |
| Axonics, INC. | $177.08 | 2021-2024 | Axonics |
| Vivus LLC | $164.98 | 2022-2024 | Qsymia |
| Intercept Pharmaceuticals, INC. | $130.68 | 2020-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $121.20 | 2025 | Camzyos |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $74.28 | 2023 | Erbe Vio3 |
| Ironwood Pharmaceuticals, INC | $73.66 | 2022-2023 | Linzess |
| Intuitive Surgical, INC. | $66.94 | 2020 | |
| Merck Sharp & Dohme LLC | $66.42 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Pentax of America, INC. | $59.33 | 2022 | |
| Celltrion USA INC. | $59.09 | 2025 | Vegzelma |
| Celgene Corporation | $58.57 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $57.07 | 2023-2024 | Compliance Endokit, Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $46.14 | 2023-2024 | Omvoh |
| Shionogi INC | $44.24 | 2019 | |
| Redhill Biopharma INC. | $44.12 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $34.79 | 2025 | Vowst, Zenpep |
| Baxter Healthcare | $34.72 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Braintree Laboratories, INC. | $31.36 | 2021-2025 | Suflave |
| Sandoz INC. | $28.96 | 2025 | |
| Grifols USA, LLC | $24.60 | 2024 | Prolastin-C Liquid |
| Alfasigma USA, INC. | $23.70 | 2020 | |
| Phathom Pharmaceuticals, INC. | $22.76 | 2025 | Voquezna |
| Ucb, INC. | $22.02 | 2019 | |
| Nestle Healthcare Nutrition INC. | $21.67 | 2023 | |
| Novo Nordisk INC | $21.36 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $21.29 | 2022 | |
| Fresenius Kabi USA, LLC | $18.43 | 2024 | Idacio |
| Ferring Pharmaceuticals INC. | $18.39 | 2023 | Rebyota |
| Daiichi Sankyo INC. | $18.01 | 2022 | |
| Echosens North America, INC. | $17.89 | 2025 | Fibroscan |
| Bayer Healthcare Pharmaceuticals INC. | $14.65 | 2024 | |
| Tela Bio, INC. | $13.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.